Total Funding
71
78
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
22773
Cardiff Oncology is develops drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers.
- Thomas H. Adams: Chairman & CEOPast Role: Gen-Probe, Chairman and CEO & Co-Founder
- Mark Erlander: Chief Executive OfficerPast Role: Hologic, Chief Scientific Officer
About the Company
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable
markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.
Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
Women Founded
